Integrated Molecular Characterization of Uterine Carcinosarcoma
Andrew D Cherniack1, Hui Shen2, Vonn Walter3
1The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
Cancer Cell
|March 16, 2017
Summary
Uterine carcinosarcomas (UCSs) exhibit extensive genomic alterations and mutations in key cancer genes. A subset shows a strong epithelial-to-mesenchymal transition (EMT) signature due to epigenetic changes, impacting therapeutic targets.
Area of Science:
- Oncology
- Genomics
- Epigenomics
- Transcriptomics
- Proteomics
Background:
- Uterine carcinosarcomas (UCSs) are aggressive tumors with complex genomic profiles.
- Understanding the molecular underpinnings of UCS is crucial for developing targeted therapies.
Purpose of the Study:
- To comprehensively characterize uterine carcinosarcomas (UCSs) using multi-omic approaches.
- To identify key genomic, epigenomic, and transcriptomic alterations driving UCS development and progression.
- To explore potential therapeutic targets within UCS molecular landscape.
Main Methods:
- Genomic, epigenomic, transcriptomic, and proteomic analyses were performed on UCS cohort samples.
- Somatic mutation profiling and copy-number alteration analysis were conducted.
- Gene expression signatures, including epithelial-to-mesenchymal transition (EMT), were assessed.
Main Results:
- UCS samples displayed extensive copy-number alterations and recurrent somatic mutations in genes such as TP53, PTEN, PIK3CA, PPP2R1A, FBXW7, and KRAS.
- A significant subset of UCS cases exhibited a strong epithelial-to-mesenchymal transition (EMT) gene signature, linked to epigenetic alterations at microRNA promoters.
- UCSs shared proteomic characteristics with other gynecologic carcinomas and sarcomas, with a notable range of EMT scores.
Conclusions:
- Uterine carcinosarcomas are characterized by significant genomic instability and mutations in frequently altered cancer genes.
- Epigenetic dysregulation contributes to a prominent EMT phenotype in a subset of UCS, influencing tumor behavior.
- The identified molecular alterations, including mutations and copy-number changes in therapeutic target genes, offer potential avenues for novel treatment strategies.
